Pharma executives cite supply chain visibility as critical solution to alleviating product loss and security concerns, while one-third are dissatisfied with current solutions.
While approximately half of pharmaceutical organizations have already deployed visibility technology to track raw materials and to better plan their manufacturing, many are dissatisfied with the capabilities of their current solutions. As a result, more than nine in 10 executives plan to implement a more robust digital supply chain visibility (SCV) solution over the next 12 months. That’s according to “The Pharmaceutical Supply Chain: Closing the Visibility Gap,” a new report issued today by FourKites, provider of the world’s leading real-time supply chain visibility platform, and Accenture.
Many existing visibility solutions fail to account for the unique nature of pharmaceutical supply chains, including cold chain shipping, raw material availability, security of shipments in transit, stringent temperature and quality control measures and high inventory costs. COVID-19 further highlighted the acute need for visibility at every node along the pharmaceutical supply chain. According to Supply Chain Dive, vaccine losses due to temperature excursions cost around $34.1 billion annually, while the United Nations reports that greater supply chain visibility into the cold chain could have saved 1 billion vaccines during the COVID pandemic.
Access the full report here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.